
|Slideshows|July 31, 2020
- MHE July 2020
- Volume 30
- Issue 7
MHE 2020 Annual Pharmacy Survey pt. 3
Author(s)MHE Staff
Listen
0:00 / 0:00
As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Third of three parts. See more in our Surveys tab.
Advertisement
Overall, the responses paint a picture of the pandemic having a major impact, which is not surprising, and reveal some optimism; for example, 78% of the respondents expect to see at least limited use of a COVID-19 vaccine by the first quarter of 2021.
Articles in this issue
over 6 years ago
Upping the Cardiovascular Health Gameover 6 years ago
New Drugs Take Aim at Autoimmune Diseasesover 6 years ago
Is the Biosimilars Waiting Game Finally Over?over 6 years ago
MHE 2020 Annual Pharmacy Survey pt. 2over 6 years ago
Racial Disparities in Cancer Enter the Spotlightover 6 years ago
MHE 2020 Annual Pharmacy Surveyover 6 years ago
Opinion: The Future of Pharmacy Care Services, Post-Pandemicover 6 years ago
Has the C-Suite Gotten Too Big?over 6 years ago
Protecting the Integrity of EHR Clinical Decision Support ToolsAdvertisement
Related to this article

A Massachusetts federal court threw out HRSA grant terms that kept Ryan White clinics from offering gender-affirming care to patients with HIV.

Only 43% of community oncologists feel very comfortable with new immunotherapies. Prerna Mewawalla, M.D., of Allegheny Health Network talks safety protocols and trial access.

Among 16 Black transgender women, 15 with HIV, risk awareness, comfort, provider trust and support shaped whether they completed HRA, according to a new qualitative study.

A Centene OB-GYN and an AAFP family physician explain how health plans, primary care and policy can help close rural maternity care gaps.

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Quick Q&A: Sarah Klein on scrutinizing PBM contracts
2
Closing rural maternity care gaps starts close to home, Centene and AAFP leaders say
3
Federal judge vacates HRSA limits on gender-affirming care in Ryan White HIV program
4
For transgender women with HIV, risk awareness and provider trust shape anal cancer follow-up
5

